NAMSW

NewAmsterdam Pharma Company N.V.

NAMSW · CIK 0001936258 · Annual (10-K) · Last 3 years

Financial Trends

Revenue$23M
20232025
Net Income−$204M
20232025
Operating CF−$148M
20232025
Free Cash Flow
20232025

Income Statement

MetricFY 2025FY 2024FY 2023
Revenue$0.0B$0.0B$0.0B
Cost of Revenue
Gross Profit
R&D Expense$0.1B$0.2B$0.2B
SG&A Expense$0.1B$0.1B$0.0B
Operating Income$-0.2B$-0.2B$-0.2B
Net Income$-0.2B$-0.2B$-0.2B
EPS (Basic)$-1.72$-2.56$-2.15
EPS (Diluted)$-1.72$-2.56$-2.15

Balance Sheet

MetricFY 2025FY 2024FY 2023
Total Assets$0.8B$0.9B$0.3B
Current Assets$0.7B$0.9B$0.3B
Cash & Equivalents$0.5B$0.8B$0.3B
Total Liabilities$0.1B$0.1B$0.1B
Current Liabilities$0.1B$0.1B$0.0B
Stockholders' Equity$0.7B$0.8B$0.3B

Cash Flow Statement

MetricFY 2025FY 2024FY 2023
Operating Cash Flow$-0.1B$-0.2B$-0.1B
Investing Cash Flow$-0.2B$-0.1B$-0.0B
Capital Expenditures
Financing Cash Flow$0.0B$0.7B$0.0B